Literature DB >> 21613482

Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.

Matthew J Winton1, Edward B Lee, Eveline Sun, Margaret M Wong, Susan Leight, Bin Zhang, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

Alzheimer's disease (AD) is characterized by the accumulation of intraneuronal tau and extracellular amyloid-β (Aβ) peptide. A triple transgenic (Tg) mouse (3xTg-AD) was reported to develop Aβ plaques and tau inclusions as well as remarkable accumulations of intracellular Aβ that were suggested to be the initiators of AD pathogenesis. However, it was unclear whether the anti-Aβ antibodies were able to distinguish Aβ peptide from the same Aβ epitopes within the amyloid precursor protein (APP). To further elucidate the identity of the immunoreactive intraneuronal material in 3xTg-AD mice, we conducted immunohistochemical, biochemical, and ultrastructural studies using a well characterized panel of antibodies that distinguish Aβ within APP from cleaved Aβ peptides. We found that the intraneuronal material shared epitopes with full-length APP but not free Aβ. To demonstrate unequivocally that this intraneuronal material was not free Aβ peptide, we generated 3xTg-AD mice deficient for β-secretase (BACE), the protease required for Aβ generation from APP. In the absence of Aβ production, robust intraneuronal APP immunostaining was detected in the 3xTg-AD/BACE(-/-) mice. Finally, we found that the formation of tau lesions was not different between 3xTg-AD versus 3xTg-AD/BACE(-/-) mice, thereby demonstrating that tau pathology forms independently from Aβ peptide generation in this mouse model. Although we cannot corroborate the presence of intraneuronal Aβ peptide in 3xTg-AD mice, our findings warrant further study as to the role of aberrant APP accumulation in this unique model of AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613482      PMCID: PMC3118598          DOI: 10.1523/JNEUROSCI.6637-10.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  BACE1 is the major beta-secretase for generation of Abeta peptides by neurons.

Authors:  H Cai; Y Wang; D McCarthy; H Wen; D R Borchelt; D L Price; P C Wong
Journal:  Nat Neurosci       Date:  2001-03       Impact factor: 24.884

Review 3.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 4.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

5.  Identification of a novel aspartic protease (Asp 2) as beta-secretase.

Authors:  I Hussain; D Powell; D R Howlett; D G Tew; T D Meek; C Chapman; I S Gloger; K E Murphy; C D Southan; D M Ryan; T S Smith; D L Simmons; F S Walsh; C Dingwall; G Christie
Journal:  Mol Cell Neurosci       Date:  1999-12       Impact factor: 4.314

6.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

7.  Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.

Authors:  T Ishihara; B Zhang; M Higuchi; Y Yoshiyama; J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

8.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

9.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Authors:  C Janus; J Pearson; J McLaurin; P M Mathews; Y Jiang; S D Schmidt; M A Chishti; P Horne; D Heslin; J French; H T Mount; R A Nixon; M Mercken; C Bergeron; P E Fraser; P St George-Hyslop; D Westaway
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

10.  Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease.

Authors:  I Grundke-Iqbal; K Iqbal; L George; Y C Tung; K S Kim; H M Wisniewski
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

View more
  56 in total

Review 1.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Early and selective impairments in axonal transport kinetics of synaptic cargoes induced by soluble amyloid β-protein oligomers.

Authors:  Yong Tang; David A Scott; Utpal Das; Steven D Edland; Kryslaine Radomski; Edward H Koo; Subhojit Roy
Journal:  Traffic       Date:  2012-02-27       Impact factor: 6.215

4.  γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.

Authors:  Fei Liu; Zhi-Qin Xue; Si-Hao Deng; Xiong Kun; Xue-Gang Luo; Peter R Patrylo; Gregory M Rose; Huaibin Cai; Robert G Struble; Yan Cai; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2013-02-22       Impact factor: 3.386

5.  Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function.

Authors:  Csilla Ari; Sergiy I Borysov; Jiashin Wu; Jaya Padmanabhan; Huntington Potter
Journal:  Neurobiol Aging       Date:  2014-02-10       Impact factor: 4.673

6.  Amyloid plaque pathogenesis in 5XFAD mouse spinal cord: retrograde transneuronal modulation after peripheral nerve injury.

Authors:  Jian-Ming Li; Zhi-Qin Xue; Si-Hao Deng; Xue-Gang Luo; Peter R Patrylo; Gregory W Rose; Huaibin Cai; Yan Cai; Xiao-Xin Yan
Journal:  Neurotox Res       Date:  2012-10-05       Impact factor: 3.911

Review 7.  "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2015-04-25       Impact factor: 3.911

8.  Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques.

Authors:  Anna Pensalfini; Ricardo Albay; Suhail Rasool; Jessica W Wu; Asa Hatami; Hiromi Arai; Lawrence Margol; Saskia Milton; Wayne W Poon; Maria M Corrada; Claudia H Kawas; Charles G Glabe
Journal:  Neurobiol Dis       Date:  2014-08-01       Impact factor: 5.996

9.  APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Authors:  Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

Review 10.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.